AU7149798A - 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cn s disorders - Google Patents

3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cn s disorders

Info

Publication number
AU7149798A
AU7149798A AU71497/98A AU7149798A AU7149798A AU 7149798 A AU7149798 A AU 7149798A AU 71497/98 A AU71497/98 A AU 71497/98A AU 7149798 A AU7149798 A AU 7149798A AU 7149798 A AU7149798 A AU 7149798A
Authority
AU
Australia
Prior art keywords
aza
bicyclo
pyridyl
disorders
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU71497/98A
Other languages
English (en)
Inventor
Merouane Bencherif
Balwinder Singh Bhatti
William Scott Caldwell
Peter Anthony Crooks
Niranjan Madhukar Deo
Gary Maurice Dull
Patrick Michael Lippiello
Alain Ravard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
RJ Reynolds Tobacco Co
Original Assignee
University of Kentucky Research Foundation
RJ Reynolds Tobacco Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/885,768 external-priority patent/US6624173B1/en
Priority claimed from US08/885,397 external-priority patent/US6525065B1/en
Application filed by University of Kentucky Research Foundation, RJ Reynolds Tobacco Co filed Critical University of Kentucky Research Foundation
Publication of AU7149798A publication Critical patent/AU7149798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU71497/98A 1997-06-30 1998-04-22 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cn s disorders Abandoned AU7149798A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/885,768 US6624173B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions for treating and/or preventing CNS disorders
US08885397 1997-06-30
US08885768 1997-06-30
US08/885,397 US6525065B1 (en) 1997-06-30 1997-06-30 Pharmaceutical compositions and methods for effecting dopamine release
PCT/US1998/008145 WO1999000385A1 (en) 1997-06-30 1998-04-22 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cns disorders

Publications (1)

Publication Number Publication Date
AU7149798A true AU7149798A (en) 1999-01-19

Family

ID=27128761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU71497/98A Abandoned AU7149798A (en) 1997-06-30 1998-04-22 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cn s disorders

Country Status (10)

Country Link
EP (1) EP0994875B1 (https=)
JP (1) JP2002511090A (https=)
AT (1) ATE261443T1 (https=)
AU (1) AU7149798A (https=)
CA (1) CA2294990C (https=)
DE (1) DE69822300T2 (https=)
DK (1) DK0994875T3 (https=)
ES (1) ES2214707T3 (https=)
PT (1) PT994875E (https=)
WO (1) WO1999000385A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
FR2791678B1 (fr) * 1999-03-30 2001-05-04 Synthelabo Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
EP1225955A1 (en) * 1999-11-01 2002-07-31 Targacept, Inc. Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors
US6890935B2 (en) 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1315493A4 (en) * 2000-08-21 2007-12-05 Univ Georgetown 2-3-DISUBSTITUTED QUINUCLIDINS AS MONOAMINE CARRIER MODULATORS AND THERAPEUTIC AND DIAGNOSTIC METHODS BASED THEREON
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
JP4923630B2 (ja) * 2006-03-02 2012-04-25 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP5413441B2 (ja) * 2011-12-09 2014-02-12 宇部興産株式会社 ４−置換テトラヒドロピランの製造方法
CN104311514B (zh) * 2014-10-14 2016-06-22 安徽扬子化工有限公司 3-羟甲基四氢呋喃酯的合成方法
CN117624393A (zh) * 2023-11-24 2024-03-01 中国科学院烟台海岸带研究所 一种吡啶基席夫碱阴离子化菊糖季铵盐及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412798A3 (en) * 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
AU7474794A (en) * 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5510355A (en) * 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
WO1996036637A1 (en) * 1995-05-17 1996-11-21 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
PT994875E (pt) 2004-06-30
WO1999000385A1 (en) 1999-01-07
ES2214707T3 (es) 2004-09-16
DE69822300T2 (de) 2005-03-10
CA2294990A1 (en) 1999-01-07
JP2002511090A (ja) 2002-04-09
DK0994875T3 (da) 2004-06-21
CA2294990C (en) 2007-03-06
EP0994875A1 (en) 2000-04-26
ATE261443T1 (de) 2004-03-15
DE69822300D1 (de) 2004-04-15
EP0994875B1 (en) 2004-03-10

Similar Documents

Publication Publication Date Title
WO2004108668A3 (en) Alpha-7 neuronal nicotinic receptor ligands: compositions and methods of use
AU7149798A (en) 3-pyridyl-1-aza-bicyclo-alkane derivatives for prevention and treatment of cn s disorders
Maelicke et al. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
Wang et al. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine 1
KR100190454B1 (ko) 모다피닐의 용도
EP1219622A3 (en) Pharmaceutical compositions for CNS and other disorders
MXPA02001306A (es) Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
EP0348360A3 (en) Pharmacological use of uridine in the treatment of nervous disorders
ZA938421B (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
PH31335A (en) Naphthalamides as central nervous system agent.
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
AU2173400A (en) Method for administering agents to the central nervous system
IL113436A0 (en) Neurotransmitter release enhancers
AU653816B2 (en) Imidazole compounds, their preparation and use
AU4038000A (en) 4-substituted quinoline derivatives as gaba receptor ligands
GB9212308D0 (en) Therapeutic compositions
Scherhaum et al. The efficacy of l-methadone and racemic methadone in substitution treatment for opiate addicts-a double-blind comparison
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
AU2278700A (en) Novel azabicyclo derivatives and their use
AU6428294A (en) Imidazoloquinoxalinone derivatives as eaa antagonists
WO2001082954A3 (en) Ceruloplasmin and uses thereof in neurodegenerative related conditions
NZ515613A (en) Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands
Orsini et al. Length of anxiolytic treatment and benzodiazepine withdrawal symptoms: A double-blind study with clotiazepam.
AU2002243310A1 (en) Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders
Bigl et al. Our experience with midazolam and flumazenil in dentistry.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase